Tatva Chintan Pharma Chem has debuted at Rs 2,111.80 on the BSE, up by 1028.80 points or 95.00% from its issue price of Rs 1083.
The scrip is currently trading at Rs 2308.00, up by 1225 points or 113.11% from its issue price. It has touched a high and low of Rs 2486.30 and Rs 2111.80 respectively. So far 6.16 lakh shares were traded on the counter.
The offering which was opened for subscription between July 16, 2021 and July 20, 2021, was oversubscribed 180 times. The massive IPO consisted of a fresh issue of Rs 225 crore and an Offer for Sale (OFS) worth Rs 275 crore by its shareholders. The issue price was fixed at Rs 1083 per share i.e. at upper end of price band of Rs 1073- 1083 apiece.
Tatva Chintan Pharma Chem is a chemical manufacturing company that manufactures structure directing agents (SDAs), phase transfer catalyst (PTCs), pharmaceutical and agrochemical intermediates, and other specialty chemicals.
| Company Name | CMP |
|---|---|
| BASF India | 3703.10 |
| Tata Chemicals | 709.05 |
| SRF | 2493.65 |
| Pidilite Inds. | 1393.25 |
| Deepak Nitrite | 1538.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: